Xhale Assurance receives FDA Clearance on Nasal AlarSp02 sensor

Top Quote Xhale Assurance Announces FDA Approval of its Second Generation Nasal AlarSpO2TM Sensor. End Quote
  • (1888PressRelease) March 20, 2015 - Xhale Assurance, Inc., developer of the patented Assurance® Nasal AlarSpO2TM Sensor, today announced FDA clearance and the global launch of its second-generation pulse oximetry sensor.

    "The Assurance® Nasal AlarSpO2TM is a true innovation in pulse oximetry," says John Moscarillo, Vice President of Xhale Assurance. "This sensor provides dependable monitoring in a wide variety of patient conditions and settings, early detection of oxygen saturations changes, and in a recent study, the sensor was validated for 7-days of continuous use which can provide substantial cost savings for the health care system."

    "Because the Assurance® Nasal Alar SpO2™ Sensor is placed at the nasal ala, it is unaffected by many of the most common conditions that cause inaccurate pulse oximetry readings," reports Dr. Richard Melker, Chief Technology Officer of Xhale Assurance. "In research studies, Nasal Alar Oximetry™ detected desaturations up to 30 seconds faster than finger-applied sensors"

  • FB Icon Twitter Icon In-Icon
Contact Information